| scholarly article | Q13442814 |
| P50 | author | Richard B S Roden | Q87305927 |
| P2093 | author name string | Ratish Gambhira | |
| Archana Monie | |||
| Chien-Fu Hung | |||
| T-C Wu | |||
| Daejin Kim | |||
| Balasubramanyam Karanam | |||
| P2860 | cites work | DNA vaccines | Q93896322 |
| The causal relation between human papillomavirus and cervical cancer | Q24673148 | ||
| Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen | Q27469893 | ||
| DNA vaccines: immunology, application, and optimization* | Q28145651 | ||
| Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP | Q28287589 | ||
| Calreticulin: not just another calcium-binding protein | Q28305104 | ||
| Papillomaviruses and cancer: from basic studies to clinical application | Q29614745 | ||
| Human papillomavirus is a necessary cause of invasive cervical cancer worldwide | Q29617514 | ||
| A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects | Q30443978 | ||
| Human papillomavirus type 16 E6-induced degradation of E6TP1 correlates with its ability to immortalize human mammary epithelial cells | Q33840139 | ||
| Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. | Q34417608 | ||
| Biological activities and molecular targets of the human papillomavirus E7 oncoprotein | Q34468787 | ||
| Persistent human papillomavirus infection and cervical neoplasia | Q34571747 | ||
| Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells | Q35854157 | ||
| Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen | Q36167792 | ||
| Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. | Q36314993 | ||
| Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity | Q36367825 | ||
| Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. | Q36684369 | ||
| Efficient intracellular assembly of papillomaviral vectors | Q36944399 | ||
| Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus | Q37423250 | ||
| Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes | Q39604102 | ||
| Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. | Q40572162 | ||
| Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens | Q40703649 | ||
| Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells | Q41532466 | ||
| Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. | Q42810754 | ||
| Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. | Q43590576 | ||
| Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe | Q43697584 | ||
| Natural history of human papillomavirus type 16 virus-like particle antibodies in young women | Q43738327 | ||
| Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine | Q60321494 | ||
| Heat shock-sensitive expression of calreticulin. In vitro and in vivo up-regulation | Q71921343 | ||
| Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors | Q73235473 | ||
| Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene | Q73519265 | ||
| Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes | Q73740013 | ||
| TAP-translocated peptides specifically bind proteins in the endoplasmic reticulum, including gp96, protein disulfide isomerase and calreticulin | Q73814928 | ||
| DNA vaccines--designer vaccines for the 21st century | Q78021965 | ||
| Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species | Q79405043 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vaccine | Q134808 |
| P304 | page(s) | 351-360 | |
| P577 | publication date | 2007-11-29 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Generation and characterization of a preventive and therapeutic HPV DNA vaccine | |
| P478 | volume | 26 |
| Q43630823 | Clinical characteristics of patients with multiple potentially human papillomavirus-related malignancies. |
| Q33589738 | Control of HPV-associated tumors by innovative therapeutic HPV DNA vaccine in the absence of CD4+ T cells |
| Q55054189 | Cutaneous Papillomaviruses and Non-melanoma Skin Cancer: Causal Agents or Innocent Bystanders? |
| Q38081358 | DNA immunization as an efficient strategy for vaccination |
| Q33680693 | DNA vaccines for cervical cancer |
| Q33756622 | DNA vaccines: developing new strategies against cancer |
| Q37200390 | Development of a DNA vaccine targeting Merkel cell polyomavirus |
| Q39021001 | Developments in L2-based human papillomavirus (HPV) vaccines |
| Q64285785 | Endoplasmic reticulum stress enhances the antigen-specific T cell immune responses and therapeutic antitumor effects generated by therapeutic HPV vaccines |
| Q46601466 | Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies |
| Q38635840 | Enhancing antitumor immunogenicity of HPV16-E7 DNA vaccine by fusing DNA encoding E7-antigenic peptide to DNA encoding capsid protein L1 of Bovine papillomavirus |
| Q37290102 | Heat-shock proteins as powerful weapons in vaccine development |
| Q37198835 | Histone deacetylase inhibitor AR-42 enhances E7-specific CD8⁺ T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination |
| Q37399767 | Immunogenicity of an HPV-16 L2 DNA vaccine |
| Q35818624 | Immunologic Control of Mus musculus Papillomavirus Type 1. |
| Q35049821 | Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses |
| Q90911275 | In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine |
| Q37010997 | Intranasal immunization with a flagellin-adjuvanted peptide anticancer vaccine prevents tumor development by enhancing specific cytotoxic T lymphocyte response in a mouse model |
| Q42673095 | Lentivirus-mediated LIGHT overexpression inhibits human colorectal carcinoma cell growth in vitro and in vivo |
| Q34639978 | Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation |
| Q37274559 | New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention |
| Q36616505 | Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated disease |
| Q37014047 | Progress and prospects for L2-based human papillomavirus vaccines |
| Q38370782 | Recent progress in vaccination against human papillomavirus-mediated cervical cancer |
| Q33907700 | Spontaneous and Vaccine-Induced Clearance of Mus Musculus Papillomavirus 1 Infection |
| Q36402453 | Strategy for eliciting antigen-specific CD8+ T cell-mediated immune response against a cryptic CTL epitope of merkel cell polyomavirus large T antigen |
| Q45886021 | The efficiency of a novel delivery system (PEI600-Tat) in development of potent DNA vaccine using HPV16 E7 as a model antigen |
| Q50115667 | Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases. |
| Q33936427 | Therapeutic HPV DNA vaccines |
| Q84504653 | Therapeutic HPV DNA vaccines |
| Q34015916 | Treatment with demethylating agent, 5-aza-2'-deoxycytidine enhances therapeutic HPV DNA vaccine potency |
| Q33627848 | Tristetraprolin: a weapon against HPV-induced cervical cancer? |
Search more.